Clinical trials
Neoplasms clinical trials
Below are recruiting neoplasms clinical trials, each written for real people, not researchers. We’re tracking 1,643 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07213791RecruitingPhase 1
Study of a new drug for FAP-positive cancers
This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.
Newport Beach, CaliforniaAges 18 years+ - NCT05734430Recruiting
Study of genetics in appendix cancer families
This study looks at genetic (inherited) and other biological factors in people with appendix cancer and, in some cases, their biological parents. The goal is to learn what may contribute to appendix cancer and help researchers better understand risk.
Nashville, TennesseeAges 18 years+ - NCT07062003Recruiting
Skin or soft tissue tumor radiation therapy using minibeams
This study tests a new type of radiation therapy, called minibeam radiation, for skin or soft tissue tumors that have come back or spread. The goal is to see if this approach can help shrink tumors while possibly sparing healthy tissue, and it's designed for people who may benefit from palliative treatment to relieve symptoms.
Rochester, MinnesotaAges 18 years+ - NCT06915727RecruitingPhase 3
Testing an imaging drug to see tumors in children having surgery
This study tests a special imaging drug called pafolacianine (Cytalux) that helps doctors see tumors more clearly during surgery. It is for children and teens who have a solid tumor in the body and are already scheduled for tumor removal or biopsy.
Rochester, MinnesotaAges 6 months–17 years - NCT06523556RecruitingPhase 1/Phase 2
Study of axatilimab with or without azacitidine for advanced blood cancers
This trial tests a new drug called axatilimab, given alone or with another drug, for people with certain blood cancers that are advanced or hard to treat. The goal is to see if this combination can help control the disease.
Columbus, OhioAges 18 years+ - NCT06400472RecruitingPhase 1
Study of drug Sofe-M for advanced solid tumors
This trial tests a new drug (Sofe-M) for people with certain advanced solid tumors, including ovarian, endometrial, cervical, lung, breast, pancreatic, or colorectal cancers. The goal is to find the best dose and see how well it works, potentially offering a new treatment option.
Scottsdale, ArizonaAges 18 years+ - NCT05440240RecruitingPhase 4
Needling and possibly steroid shot for Dupuytren’s hand tightness
This trial tests a minimally invasive procedure that uses a needle to release tight tissue in the hand, and may include a steroid injection. It aims to improve hand finger straightening for people with Dupuytren’s contracture.
SilkeborgAges 45–99 - NCT04519151RecruitingPhase 2
Pembrolizumab plus lenvatinib for ovarian cancer that returned
This Phase 2 trial tests whether pembrolizumab plus lenvatinib can shrink ovarian cancer that has come back after platinum chemotherapy. You may be eligible if your cancer returned after a certain “time off” from prior treatment and you meet key health and safety requirements.
Ramat GanAges 18 years+ - NCT04493632Recruiting
Registry for an OncoSil implant in locally advanced pancreatic cancer
This observational registry tracks patients with locally advanced, unresectable pancreatic cancer who receive an OncoSil implant and then start standard chemotherapy. It may help doctors understand how the implant is used in real life and how patients do over time.
Las Palmas de Gran CanariaAges 18–90 - NCT06523582Recruiting
Genetic study of neuroendocrine tumors in Mexican patients
This study aims to find genetic causes of neuroendocrine tumors in Mexican patients. By understanding your DNA, researchers hope to improve diagnosis and treatment for people with these rare conditions.
Mexico City, Mexico CityAges 18 years+ - NCT07222800RecruitingPhase 3
Testing a new drug plus chemo for stage 4 colorectal cancer
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
Chandler, ArizonaAges 18 years+ - NCT06988943Recruiting
Finding lung cancer early with CT screening in Guangzhou communities
This study is testing a way to find lung cancer early by offering free CT scans to people in certain communities in Guangzhou. It helps catch cancer before symptoms start.
Guangzhou, GuangdongAges 40–74 - NCT06674811Recruiting
Childhood cancer surgery recovery study
This study looks at how children and young adults recover after surgery for solid tumors. It also includes their caregivers to understand how resilience affects recovery.
Rochester, MinnesotaAges 3–25 - NCT06661915RecruitingPhase 2
Combination treatment for advanced myeloproliferative neoplasms
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
Irvine, CaliforniaAges 18 years+ - NCT06349642Recruiting
Testing a live tumor test for immune therapy response
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Phoenix, ArizonaAges 18 years+ - NCT04780256Recruiting
Study of removing digestive tumors with an endoscopy procedure
This trial looks at people (18 or older) who already had a digestive tract tumor removed using an endoscopy procedure. It may help doctors learn how this approach works and what outcomes to expect after removal.
Reggio Emilia, REAges 18–100 - NCT05770102RecruitingPhase 2/Phase 3
Atezolizumab for cancers with high mutation or immune markers
This trial tests atezolizumab, a cancer immunotherapy, for people whose tumors have high mutation levels (TMB), or are “MSI-high,” or have CMMRD. It may help shrink cancer or slow its growth by boosting the immune system’s ability to recognize the tumor.
BelfastAges Any age - NCT05857995Recruiting
Personalized survivorship care program for rural lung cancer survivors
This study tests a personalized care program to help people who have had lung cancer manage life after treatment. It focuses on survivors living in rural areas, aiming to improve follow-up care and support.
Lexington, KentuckyAges 18 years+ - NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT05386108RecruitingPhase 1/Phase 2
Test abemaciclib plus elacestrant for breast cancer brain spread
This trial studies whether the combination of abemaciclib and elacestrant can slow or shrink ER-positive, HER2-negative breast cancer that has spread to the brain. It is designed for people whose cancer has progressed despite prior hormone (endocrine) treatment.
Fullerton, CaliforniaAges 18 years+ - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Birmingham, AlabamaAges 1–21 - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Birmingham, AlabamaAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT03303495RecruitingPhase 3
Second-line chemo with or without bevacizumab for colon cancer
This Phase 3 study compares two treatment plans for people with metastatic colorectal cancer that got worse or caused side effects after first chemotherapy. It looks at whether adding bevacizumab (a medicine that targets blood vessels feeding tumors) improves outcomes versus using a different chemotherapy approach.
Guangzhou, GuangdongAges 18 years+
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neoplasms?
- Yes. Clin2 currently lists 1,643 recruiting neoplasms studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neoplasms trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neoplasms trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.